[Treatment of bone metastatic pain with Sm153-EDTMP. Evaluation of the analgesic response and the existence of differences according to the primary tumor and the metastatic pattern]. / Tratamiento del dolor óseo metastásico con Sm153-EDTMP. Valoración de la respuesta analgésica y de la existencia de diferencias según el tipo de tumor y el patrón metastásico.
Rev Esp Med Nucl
; 24(5): 297-304, 2005.
Article
em Es
| MEDLINE
| ID: mdl-16194461
ABSTRACT
AIMS:
To evaluate the response to Sm153-EDTMP treatment in patients with metastatic bone pain and the existence of differences in the response according to the scintigraphic pattern (99mTc-MDP) and the primary tumor. MATERIAL ANDMETHODS:
We have evaluated the response to Sm153-EDTMP treatment in 32 patients (17 male and 15 female) who received 38 doses (1 mCi/kg). The primary tumor was prostate cancer in 15 patients, breast in 13, lung in 2, intestinal carcinoid in one and unknown in one. Two types of response were considered a) effective and b) non-effective. Patients were classified into 3 groups according to the metastatic pattern 1) Superscan (SS), 2) Generalized metastases (GM) and 3) Regional metastases (RM).RESULTS:
There was effective response in 24 doses (63.15%) and non-effective in 14 (36.84%). The mean duration of the response was 12.08 weeks. Patients with GM pattern showed 16 effective responses (76.19%) and 5 non-effective (23.8%). In SS pattern there were 6 effective responses (60%) and 4 non-effective (40%) and 2 effective (28.57%) and 5 non-effective (71.53%) in RM pattern. These differences did not reach statistical significance (p > 0.05). We did not find differences in the response between prostate cancer (12 effective and 6 non-effective) and breast cancer (10 effective and 6 non-effective) (p = 0.79968).CONCLUSIONS:
Sm153-EDTMP treatment is efficacious in patients with metastatic bone pain with effective response in 63.15% of the treatments. The response percentage was lower in patients with RM pattern but the differences did not reach statistical significance. There were no differences in the response between prostate and breast cancer patients.
Buscar no Google
Bases de dados:
MEDLINE
Assunto principal:
Compostos Organometálicos
/
Compostos Organofosforados
/
Dor
/
Neoplasias Ósseas
/
Analgésicos não Narcóticos
/
Analgesia
Tipo de estudo:
Etiology_studies
Limite:
Adult
/
Aged
/
Aged80
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
Es
Revista:
Rev Esp Med Nucl
Assunto da revista:
MEDICINA NUCLEAR
Ano de publicação:
2005
Tipo de documento:
Article